OncoSec Medical Inc (ONCSQ)

[lasers]

OncoSec Medical's Intratumoral Plasmid IL-12 Demonstrates Effectiveness at Enhancing Tumor Immunogenicity in Preclinical Tumor ModelsData Presented at Keystone Symposia Conference "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology"
PR NEWSWIRE 2:01 PM ET 3/21/2017
Symbol Last Price Change
ONCS 1.29up +0.02 (+1.57%)
QUOTES AS OF 04:00:00 PM ET 03/21/2017
SAN DIEGO , March 21, 2017 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") , a company developing DNA-based intratumoral cancer immunotherapies, today presented a poster titled "Intratumoral Electroporation-mediated IL-12 Gene Therapy Can Enhance Tumor Immunogenicity" (Poster #2074), at the Keystone Symposia Conference, "Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology," in Whistler, British Columbia, Canada. The poster included preclinical data demonstrating that in vivo electroporation of intratumoral plasmid IL-12 (ImmunoPulse® IL-12) enhances immunogenicity in poorly immunogenic mouse cancer models. For more information about this meeting, please visit http://keystonesymposia.org.

"These data support the hypothesis that intratumoral delivery of plasmid IL-12 with electroporation can alter the tumor's immune environment in such a way that a 'cold' non-immunogenic tumor is converted to a 'hot' immunogenic tumor, thus further supporting recent clinical data that ImmunoPulse IL-12 is a rational combination therapy with anti-PD-1 checkpoint therapies," said Punit Dhillon, President and CEO. "Also, generation of an antigen-specific CD8 T-cell response provides evidence for a potential mechanism of action for the abscopal responses seen in both preclinical and clinical settings."

The full-text abstract is available on the Publications section of OncoSec's website (www.oncosec.com).